Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
01 February 2018Website:
http://www.sol-gel.comNext earnings report:
13 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 2 min agoDividend
Analysts recommendations
Institutional Ownership
SLGL Latest News
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.
NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company specializing in treatments for severe skin conditions, is currently conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome. In addition to their two approved large-category dermatology products, TWYNEO® and EPSOLAY®, Sol-Gel announced today that they have entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. Ltd. in China for the commercialization of TWYNEO for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.
What type of business is Sol-Gel Technologies?
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
What sector is Sol-Gel Technologies in?
Sol-Gel Technologies is in the Healthcare sector
What industry is Sol-Gel Technologies in?
Sol-Gel Technologies is in the Biotechnology industry
What country is Sol-Gel Technologies from?
Sol-Gel Technologies is headquartered in Israel
When did Sol-Gel Technologies go public?
Sol-Gel Technologies initial public offering (IPO) was on 01 February 2018
What is Sol-Gel Technologies website?
https://www.sol-gel.com
Is Sol-Gel Technologies in the S&P 500?
No, Sol-Gel Technologies is not included in the S&P 500 index
Is Sol-Gel Technologies in the NASDAQ 100?
No, Sol-Gel Technologies is not included in the NASDAQ 100 index
Is Sol-Gel Technologies in the Dow Jones?
No, Sol-Gel Technologies is not included in the Dow Jones index
When was Sol-Gel Technologies the previous earnings report?
No data
When does Sol-Gel Technologies earnings report?
The next expected earnings date for Sol-Gel Technologies is 13 March 2025